When can I resume sex after laser/RF or injectable treatments?
When can I resume sex after laser/RF or injectable treatments? Most people wait until any spotting or tenderness has settled—often 3–7 days after gentle radiofrequency/laser and 3–5 days after superficial injectables (PRP or polynucleotides). Go slower if tissues feel sensitive; use generous lubricant and stop if there’s sting. Your own comfort and absence of red flags matter most. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
When can I resume sex after laser/RF or injectable treatments? In the context of genitourinary syndrome of menopause (GSM), a sensible rule is to wait until tissues feel calm and any spotting, oozing or marked tenderness has passed. For most, that is around 3–7 days after gentle vaginal radiofrequency or fractional laser, and 3–5 days after superficial vestibular/vaginal injectables such as platelet-rich plasma (PRP) or polynucleotides. If you had deeper or more extensive work, your clinician may advise longer. Comfort, not the calendar, should be your green light.
Why waiting a few days helps. Energy devices create a controlled thermal effect to nudge collagen remodelling; injectables can leave pinpoint bruising. Immediate sex or intense friction can feel sharper on freshly treated epithelium and may prolong irritation. A brief pause allows micro-injury to settle so you start again on a calmer baseline rather than “testing the area” while it is still reactive.
A step-by-step way to restart comfortably. Day 1–2: keep the area clean with lukewarm water; avoid fragranced products. Day 3–5: if there is no spotting, try low-friction activities first (walking, cycling with extra padding/lubricant if needed). When intimacy resumes, begin with external touch and shallow positions, add a pea of lubricant directly to the vestibule (entrance) plus internal glide, and pause at the first hint of sting. Many find a silicone-based lubricant provides the longest glide for a tender entrance; water-based is versatile and condom-friendly; oil-based feels rich but can degrade latex condoms/toys.
Placement matters more than brand. If your discomfort is “paper-cut” splits at the posterior fourchette, target care precisely: moisturiser or local oestrogen cream to the vestibule as well as internally; lubricant at the entrance before and during activity; and avoid high-friction angles initially. Internal-only care often misses the hotspot, which is why some people feel no benefit despite the right product on paper.
Support the biology while you heal. GSM is a biology problem (low oestrogen → thinner, less elastic epithelium; higher pH; fewer Lactobacillus) and a mechanics problem (friction, micro-tears, dyspareunia). While procedures address tissue mechanics or conditioning, ongoing foundations—a scheduled vaginal moisturiser 2–4 nights weekly and a compatible lubricant—plus, when acceptable, local vaginal oestrogen or vaginal DHEA make resuming sex smoother and help benefits last. See an overview of how treatment steps are sequenced, and plan reviews and budgets via treatment prices.
Individual factors that may lengthen the pause. If you’re on anticoagulants you may bruise more after injectables; if you have device-specific considerations (e.g., certain implants for RF) or you recently had pelvic/perineal surgery, you may be advised to defer procedures and/or extend the abstinence window. Active infection (BV, thrush, UTI), malodorous discharge, fever or new post-menopausal bleeding are reasons to pause and seek assessment before any intimacy.
What to expect when you start again. Early encounters should be short, well-lubricated and adjustable. Use positions with control of angle and depth; add pillows to reduce focal pressure; re-apply lubricant if glide fades. If sting appears, stop immediately rather than “pushing through”—that protects confidence and tissue. Keep a short diary (sting with urine contact, micro-tears, depth/angle that felt easy) and bring it to your review (typically 6–12 weeks after treatment).
When timelines feel slow. If you still feel sore after two weeks, re-check basics: Are you using moisturiser regularly? Is your lubricant compatible with your barrier method and placed at the vestibule? Are fragranced washes/liners or tight sports kit keeping irritation alive? Consider pelvic health physiotherapy if a protective pelvic floor clench developed after previous pain; neither laser/RF nor injectables relax muscles. If discharge is green/grey and malodorous, itch is intense with thick white discharge, there is visible blood in urine, fever or new post-menopausal bleeding, seek assessment.
Clinical Context
Who can resume sooner (3–5 days)? People who had limited, superficial vestibular injectables or very gentle RF/laser, feel settled by day 3–5, and have no spotting or tenderness on light touch. Start with external focus and add shallow, adjustable positions with generous lubricant.
Who should wait longer (up to 1–2 weeks)? Those with lingering tenderness/spotting, more extensive internal treatment, anticoagulant use with bruising, or a history of micro-tears at the entrance. Anyone with infection signs or new post-menopausal bleeding should pause and seek review before any intimacy.
Next steps in practice. Keep cleansing gentle (lukewarm water; bland emollient as a soap substitute), schedule a moisturiser, and choose a lubricant that suits your needs—water-based (versatile/condom-friendly) or silicone-based (longest glide). Resume gradually, prioritise comfort signals, and book a follow-up to fine-tune placement, technique and pacing.
Evidence-Based Approaches
Patient-friendly basics: The NHS explains symptoms, self-care and red flags for vaginal dryness, reinforcing lubricant/moisturiser first principles and when to seek help.
Guideline framing (UK): The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; local options can be used with or without HRT.
Device oversight: UK expectations around intended use, vigilance and safety reporting for medical devices are outlined by the national regulator; see the MHRA medical devices pages, which underpin prudent aftercare and red-flag advice after energy-based treatments.
Effectiveness benchmarks: Comparative evidence summarised by the Cochrane Library shows local vaginal oestrogens improve dryness, soreness, dyspareunia and pH versus placebo; this provides context for continuing biology support as procedures settle.
Pathophysiology & placement: Peer-reviewed overviews indexed on PubMed describe GSM mechanisms (thinner epithelium, higher pH, reduced lactobacilli) and support vestibule-aware placement and stepwise resumption of sex to minimise micro-tears.